CYP19A1 and breast carcinoma: Although suitable endocrine therapy with tamoxifen or aromatase inhibitor can effectively increase the survival rate of breast cancers, studies have clarified many molecular mechanisms that cause endocrine-therapy resistance.36 There is an urgent requirement for an in-depth study of the relapse mechanisms for the endocrine therapy.